AlconXSWX:ALCE +3.65%53 EBIT per Share is CHF1.93 as of Mar. 2026. GuruFocus rates XSWX:ALCE with a GF Score™ of 53/100 and a GF Value™ of CHF73.46 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 689 Medical Devices & Instruments companies, Alcon ranks better than 64.88% on this metric.
Alcon's EBIT per Share for the
three
months ended in Mar. 2026 was CHF0.47.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was CHF1.93.
During the past 12 months, the average EBIT per Share Growth Rate of Alcon was -28.50% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 19.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Alcon's EBIT per Share or its related term are showing as below:
XSWX:ALCE'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -77.7 Med: 19.9 Max: 32.7
Current: 19.9
During the past 10 years, the highest 3-Year average EBIT per Share Growth Rate of Alcon was 32.70% per year. The lowest was -77.70% per year. And the median was 19.90% per year.
XSWX:ALCE's 3-Year EBIT Growth Rate is ranked better than 64.88% of 689
companies
in the Medical Devices & Instruments industry
Industry Median: 9.6
vs XSWX:ALCE: 19.90
Alcon's EBIT for the
three
months ended in Mar. 2026 was CHF230 Mil.
Alcon (XSWX:ALCE) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Alcon EBIT per Share Related Terms
Alcon EBIT per Share Historical Data
* Premium members only.
The historical data trend for Alcon's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF1.93
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alcon (XSWX:ALCE) has a EBIT per Share of CHF1.93 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Alcon and its competitors. According to the industry distribution chart, Alcon ranks #242 out of 689 companies in the Medical Devices & Instruments industry, placing it in the top 35.1%.
Is Alcon's EBIT per Share too high?
Alcon's current EBIT per Share is CHF1.93. Based on the distribution chart, Alcon ranks #242 out of 689 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Alcon has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alcon's EBIT per Share compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Alcon ranks #242 out of 689 companies for EBIT per Share. This puts Alcon in the upper half of its industry. The industry median EBIT per Share is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.60, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Alcon and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alcon's current EBIT per Share is CHF1.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alcon stock overvalued right now?
Based on GuruFocus' analysis, Alcon (XSWX:ALCE) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF73.46, compared to a current price of CHF55.60 — trading 24.3% below its estimated fair value. The current EBIT per Share is CHF1.93. Alcon's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Alcon (XSWX:ALCE), the current EBIT per Share is CHF1.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alcon (XSWX:ALCE) Overvalued in 2026?
Based on GuruFocus' analysis, Alcon stock appears to be undervalued.
The current stock price of CHF55.60 is trading 24.3% below its estimated GF Value™ of CHF73.46.
GuruFocus considers Alcon to be Modestly Undervalued.
Key valuation signals for XSWX:ALCE:
EBIT per Share: CHF1.93
GF Value™: CHF73.46 vs. price of CHF55.60 (24.3% below fair value)
No single metric tells the full story. See the XSWX:ALCE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
53GF Score
Get the complete analysis for XSWX:ALCE
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ALCE has been successfully added to your 
